A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
SUMMARY The precise control of CRISPR-Cas9 activity is required for a number of genome engineering technologies. Here, we report a generalizable platform that provided the first synthetic small-molecule inhibitors of Streptococcus pyogenes Cas9 (SpCas9) that weigh <500 Da and are cell-permeable, reversible, and stable under physiological conditions. We developed a suite of high-throughput assays for SpCas9 functions, including a primary screening assay for SpCas9 binding to the protospacer adjacent motif and used these assays to screen a structurally diverse collection of natural-product-like small molecules to ultimately identify compounds that disrupt the SpCas9-DNA interaction. Using these synthetic anti-CRISPR small molecules, we demonstrated dose and temporal control of SpCas9 and catalytically-impaired SpCas9 technologies, including transcription activation, and identified a pharmacophore for SpCas9 inhibition using structure-activity relationships. These studies establish a platform for rapidly identifying synthetic, miniature, cell-permeable, and reversible inhibitors against both SpCas9 and next-generation CRISPR-associated nucleases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437 · cited 1×
“The ease of targeting catalytically impaired SpCas9 to any genomic locus has resulted in transformative technologies (Komor et al., 2016; Wang et al., 2016).”
Self-citationWang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495 · cited 1×
“First, in germline editing, restricting SpCas9 activity to a narrow temporal window is important, as persistent activity in dividing cells contributes to mosaicism (Wang et al., 2013; Yen et al., 2014).”
BackgroundHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292 · cited 1×
“PEST cell line in which eGFP knockout by SpCas9 led to a loss of fluorescence (Fu et al., 2013; Kleinstiver et al., 2015a); in this cell line, the percentage of eGFP-negative cells correlates with SpCas9 activity.”
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825 · cited 3×
“After optimizing the inhibition of the nuclease activity of the SpCas9:gRNA complex, we sought to optimize for inhibition of the transcriptional activation complex, which consists of dCas9:gRNA and transcription-activating SAM domains (Konermann et al., 2015) that are recruited by the gRNA.”
MethodInfluentialCrystal structure of Cas9 in complex with guide RNA and target DNA
Nishimasu, H., Ran, F. A., Hsu, P. D., Konermann, S., Shehata, S. I., Dohmae, N., Ishitani, R., Zhang, F., & Nureki, O. (2014) · Cell · doi:10.1016/j.cell.2014.02.001 · Cited by 2,306 · cited 1×
“Fourth, SpCas9 possesses novel protein folds, limiting the ability to leverage existing rational design approaches (Nishimasu et al., 2014).”
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624
Pattanayak, V., Lin, S., Guilinger, J. P., Ma, E., Doudna, J. A., & Liu, D. R. (2013) · Nature Biotechnology · doi:10.1038/nbt.2673 · Cited by 1,487
Therapeutic genome editing: prospects and challenges
Cox, D. B. T., Platt, R. J., & Zhang, F. (2015) · Nature Medicine · doi:10.1038/nm.3793 · Cited by 1,336
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0326-x · Cited by 1,093
Cited by
Base editing: advances and therapeutic opportunities
Porto, E. M., Komor, A. C., Slaymaker, I. M., & Yeo, G. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0084-6 · Cited by 476
Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9 genome editing
Liu, B., Chen, S., Rose, A. L., Chen, D., Cao, F., Zwinderman, M., Kiemel, D., Aïssi, M., Dekker, F. J., & Haisma, H. J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkz1136 · Cited by 370
Theory and applications of differential scanning fluorimetry in early-stage drug discovery
Gao, K., Oerlemans, R., & Groves, M. R. (2020) · Biophysical Reviews · doi:10.1007/s12551-020-00619-2 · Cited by 263
Titrating gene expression using libraries of systematically attenuated CRISPR guide RNAs
Jost, M., Santos, D. A., Saunders, R. A., Horlbeck, M. A., Hawkins, J. S., Scaria, S. M., Norman, T. M., Hussmann, J. A., Liem, C. R., Gross, C. A., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0387-5 · Cited by 164
Lopes, R., & Prasad, M. K. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1339189 · Cited by 82
“Over 80 naturally occurring Acr proteins have been identi fi ed (Jia and Patel, 2021), and one synthetic small molecule inhibitor was discovered through high-throughput screening (Maji et al., 2019).”
Background
Metadata
- Authors
- Maji, B., Gangopadhyay, S. A., Lee, M., Shi, M., Wu, P., Heler, R., Mok, B., Lim, D., Siriwardena, S. U., Paul, B., Dančík, V., Vetere, A., Mesleh, M. F., Marraffini, L. A., Liu, D. R., Clemons, P. A., Wagner, B. K., & Choudhary, A.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 177
- Issue
- 4
- Pages
- 1067-1079.e19
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2942965435
- Cited by
- 188
- References
- 15
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9. https://app.cochat.ai/papers/10.1016/j.cell.2019.04.009
- The paper
- Maji, B., Gangopadhyay, S. A., Lee, M., Shi, M., Wu, P., Heler, R., Mok, B., Lim, D., Siriwardena, S. U., Paul, B., Dančík, V., Vetere, A., Mesleh, M. F., Marraffini, L. A., Liu, D. R., Clemons, P. A., Wagner, B. K., & Choudhary, A. (2019). A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9. Cell. https://doi.org/10.1016/j.cell.2019.04.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.